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The goal of this study was to determine the degree to which the persistence of cryptococcosis, overall 1-year mortality, and 1-year
mortality due to cryptococcosis were influenced by initial antifungal treatment regimen in a cohort of adults with cryptococcosis
treated at a tertiary care medical center. Risk factors, underlying conditions, treatment, and mortality information were ob-
tained for 204 adults with cryptococcosis from Duke University Medical Center (DUMC) from 1996 to 2009. Adjusted risk ratios
(RR) for persistence and hazard ratios (HR) for mortality were estimated for each exposure. The all-cause mortality rate among
patients with nonsevere disease (20%) was similar to that in the group with disease (26%). However, the rate of cryptococcosis-
attributable mortality with nonsevere disease (5%) was much lower than with severe disease (20%). Flucytosine exposure was
associated with a lower overall mortality rate (HR, 0.4; 95% confidence interval [CI], 0.2 to 0.9) and attributable mortality rate
(HR, 0.5; 95% CI, 0.2 to 1.2). Receiving a nonrecommended antifungal regimen was associated with a higher relative risk of per-
sistent infection at 4 weeks (RR, 1.9; 95% CI, 0.9 to 4.3), and the rate of attributable mortality among those not receiving the rec-
ommended dose of initial therapy was higher than that of those receiving recommended dosing (HR, 2.3; 95% CI, 1.0 to 5.0).
Thus, the 2010 Infectious Diseases Society of America (IDSA) guidelines are supported by this retrospective review as a best-
practice protocol for cryptococcal management. Future investigations should consider highlighting the distinction between all-
cause mortality and attributable mortality so as not to overestimate the true effect of cryptococcosis on patient death.
The optimal antifungal treatment strategy for patients withcryptococcosis remains in question despite the 2010 Infectious
Diseases Society of America (IDSA) guidelines (1). Treatment of
cryptococcal meningoencephalitis is based on a small number of
clinical trials, but most of the recent studies have been in resource-
limited areas and may not reflect the situation with newer antifun-
gals in advanced medical settings (2–5). Previous studies have
suggested that treatment is generally 50 to 80% effective (6–10),
that antifungal drugs cause toxicities in roughly one-third of cases,
that the rate of mortality while on antifungal therapy remains high
(approximately 20%), and that mortality varies considerably by
the host underlying immune status (11–14).
There have been few comprehensive, comparative studies of
cryptococcosis that encompass all three risk groups (HIV positive,
solid-organ transplantation, and HIV negative/nontransplant)
with and without meningeal involvement, identified by the 2010
IDSA guidelines in the era of lipid products of amphotericin B.
Therefore, we examined the effectiveness of initial antifungal
treatment among these three clinical groups within a single study
center. The primary aim of this study was to determine the degree
to which the risk for persistence of cryptococcosis and rates of
1-year mortality and mortality due to cryptococcosis were influ-
enced by the initial antifungal treatment regimen in a cohort of
patients with cryptococcosis treated at a tertiary care medical cen-
ter. The advantage of this approach was the ability to observe
real-world treatment strategies and compare risk groups where
anticryptococcal drugs are available and the general care and man-
agement of this infection has been relatively consistent over the
14-year study period. Other treatment-related outcomes exam-
ined were (i) changes from initial therapy to definitive therapy, (ii)
development of renal toxicity, (iii) development of immune re-
constitution inflammatory syndrome (IRIS), and (iv) number of
cases requiring multiple courses of induction therapy using am-
photericin B.
MATERIALS AND METHODS
Study population. All consecutive 204 adults hospitalized with crypto-
coccosis and who were treated at Duke University Medical Center
(DUMC) were enrolled in the cohort using International Classification of
Diseases, ninth revision (ICD-9) (15), discharge codes of cryptococcosis
(117.5) and cryptococcal meningitis (321.0) from 1996 to 2009. Three
identified patients were excluded from this cohort because they had died
prior to receiving any anticryptococcal therapy or refused treatment at
DUMC. Risk factors, underlying conditions, treatment, and mortality in-
formation were obtained by chart review. Patients presented to DUMC,
were diagnosed with cryptococcosis, and were assessed for severity of
disease prior to starting treatment. “Severe” and “nonsevere” cryptococ-
cosis disease categories divided patients who required induction therapy
with amphotericin B (severe disease) and those for whom fluconazole was
indicated as the primary therapy (nonsevere disease) based on the IDSA
guidelines (1), whether or not the patients actually received the indicated
treatment. To be defined as severe cases, patients had evidence of central
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nervous system (CNS) involvement with or without cryptococcemia or
dissemination with evidence of high fungal burden based on serum cryp-
tococcal antigen (CRAG) titers of 1:512). Nonsevere cases had no CNS
involvement, evidence of pulmonary disease, or cryptococcemia or dis-
semination and CRAG titers of 1:512. For severe disease patients, flucy-
tosine (5FC) combination therapy exposure was assessed separately from
primary therapy for a more in-depth examination restricted to this severe
group. Thus, “appropriate” or “recommended” initial treatment was am-
photericin B based for severe disease patients and fluconazole based for
nonsevere disease patients. Follow-up started when initial treatment was
given, preceded by the occurrence of disease, patient admission, and as-
sessment of cryptococcosis severity.
Exposures. There were three main treatment exposures of interest: (i)
appropriate initial treatment, (ii) appropriate initial treatment dose, and
(iii) appropriate flucytosine use based on IDSA recommendations. Sec-
ondary treatment-related exposures of interest included the completion
of at least 7 days of flucytosine combination antifungal therapy versus not
receiving it or completing 7 days (confined to patients with severe dis-
ease), completion of at least 30 days of fluconazole therapy among surviv-
ing patients (nonsevere disease), and completion of at least 90 days of
fluconazole therapy among surviving patients (nonsevere disease).
Patients were categorized by whether or not their initial antifungal
drug and dosing were appropriate using the 2010 IDSA guidelines. Flucy-
tosine exposure at the start of induction therapy was assessed among
patients with severe disease. “Initial therapy” refers to the first antifungal
drug administered at the start of induction treatment. This excludes sub-
sequent switching from this initial drug to another formulation during the
same induction period (e.g., deoxycholate to lipid amphotericin B). An
exception to this definition was the use of fluconazole prior to confirma-
tion of disease, in which case a patient was then placed on an amphotericin
B regimen. Furthermore, fluconazole exposure was not considered as ini-
tial therapy if it was administered for 5 days after the first positive cul-
ture result before amphotericin B began, or else fluconazole would be
considered as initial therapy. This exception was made for three patients
with severe disease.
In order to account for initial dosing adjustments that can occur in the
first few days of induction, the averaged dose of continuous antifungal
therapy (no change of drug or interruption of treatment for 3 days) was
used to define acceptable dosing of initial therapy. If there was a change
from initial therapy (excluding flucytosine), then only the first drug and
its corresponding average dosing were used to examine appropriate initial
therapy dose. Acceptable dosing was defined as follows: 0.7 to 1.0 mg/kg of
body weight/day amphotericin B deoxycholate (AmpBd), 3 to 6 mg/kg/
day liposomal AmpB (L-AmpB), 4 to 6 mg/kg/day AmpB lipid complex
(ABLC), and 400 mg/day fluconazole. Rounding to the nearest tenth for
AmpBd and the nearest integer for AmpB lipid products was used to
categorize appropriate dosing. Dosing of flucytosine was not examined in
this study. Cumulative doses among patients who survived long enough
to complete the recommended length of treatment (14 days for severe and
90 days for nonsevere) were summarized (see the supplemental material).
Outcomes. Follow-up time started when anticryptococcal therapy
was initiated after patient admission, diagnosis, and severity evaluation
were complete. We assessed persistent infection at 2 (severe disease only)
and 4 weeks and cryptococcal-attributable mortality and all-cause mor-
tality through 1 year of follow-up. Two and 4 weeks were chosen because
severe-disease patients are recommended to receive at least 2 weeks of
induction therapy and reliable follow-up and mortality information was
available for the majority of surviving patients. Figure 1 illustrates overall
patient flow. Follow-up for this study began at the start of anticryptococ-
cal therapy and continued up to 4 weeks to evaluate persistence and up to
1 year for mortality outcomes.
Persistent cryptococcosis was defined as having a positive culture(s) 2
weeks after starting therapy (among the severe disease group only), and
persistent cryptococcosis at 4 weeks was defined as having a positive cul-
ture(s) and/or positive indication of the presence of cryptococcus-related
symptoms 4 weeks after starting therapy. Patients had to have survived
until the time of measurement to be included in the analysis. Data were
observational; measures for indicating persistent infection were not taken
at exactly 2 weeks and 4 weeks to test for positive culture, CRAG, and/or
infection-related symptoms. Acceptable values were used if they did not
overlap the preceding measurement (e.g., a baseline culture could not be
used for a 2-week test result) and did not extend beyond the designated
time point (e.g., a 3-week measure would be counted not as a 2-week
measure but instead as a 4-week measure if there was not an observation at
4 weeks). Persistence measures for 2 weeks had to have occurred at 1
week of therapy. Measures beyond the final time point (4 weeks) were
accepted for that final time point if it was within 90 days since the start of
therapy.
In order to assess 1-year mortality, we obtained data on survival and
mortality up to 1 year after the date of cryptococcosis diagnosis from the
Duke Data Support Repository (DSR), which uses the Social Security
Administration death index, the Tumor Registry, and The Duke Informa-
tion System for Cardiovascular Care death data to report mortality status.
If the patient died beyond 1 year of follow-up or was alive or lost to
follow-up at the end of the study period, they were censored subjects.
Attributable mortality within 1 year from the start of anticryptococcal
therapy was determined on the basis of the finding by a panel of experts
that death was due to conditions related to at least one of the following:
increased CNS pressure, persistent infection, relapse of infection while on
treatment for cryptococcosis and an underlying disease, or organ failure
while on antifungal treatment.
Additional outcomes for both severe and nonsevere cryptococcosis
patients included frequency of reinduction(s) with amphotericin B, IRIS,
and renal toxicity during initial therapy. Renal toxicity was defined as a
50% decrease in the glomerular filtration rate (GFR), also known as
estimated creatinine clearance, during initial induction treatment. GFR
FIG 1 Diagram of patient flow scenarios from entry through 1 year of follow-up. Upon entry into the cohort, patient underlying condition(s) and severity of
cryptococcosis were assessed. Three patients did not undergo antifungal therapy and were excluded from this treatment effectiveness study. Follow-up began at
the start of therapy, and patients were subsequently evaluated for persistence, mortality rate, and secondary outcomes, such as renal toxicity (among severe
disease patients taking amphotericin B) and IRIS, through 1 year.
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was calculated using the CKD-EPI (Chronic Kidney Disease Epidemiol-
ogy Collaboration) formula (16). For patients with severe disease who
received induction therapy with amphotericin B, creatinine values closest
to day 0 and day 14 of treatment were used to determine renal toxicity. The
definition for IRIS (adapted from reference 17) has been described else-
where (18).
For severe and nonsevere disease groups, the dynamics of changing
from one treatment regimen to another were compared to findings for
patients who received uninterrupted antifungal therapy. Lastly, we esti-
mated the association between patients who received 0 to 7 days of flucy-
tosine and those who received more than 7 days of flucytosine with regard
to the risks of persistence and mortality among 2-week survivors with
severe disease.
Data analysis. To evaluate issues of confounding, we assessed the bi-
variate associations between all covariates and main exposures and out-
comes. Minimum adjustment sets were determined using Directed Acy-
clic Graph (DAG) program (version 0.21) (19). However, the program
resulted in 14 confounders in the minimum adjustment sets for each of
our three chosen exposures (with slight variation; see Fig. S1 and S2 in the
supplemental material), which our limited study size could not operably
model. Based on previous studies that predicted poor outcomes (9, 10, 14,
20–24), we prioritized variables associated with severe underlying condi-
tion and high fungal burden from our minimal adjustment sets and pro-
ceeded with multivariate adjustment using a change-in-estimate ap-
proach with a 10% cutoff criterion (25), eliminating variables chosen by
the DAG program that did not confound the association of effect esti-
mates between the main exposures and outcomes. Changes in the preci-
sion of estimates were examined with the confidence limit ratio (CLR);
covariates that improved precision were maintained in the final model.
Effect measure modification by confounding variables was examined
through the inclusion of interaction terms in the models and using the
spreadsheet by Andersson et al. to determine the relative excess risk due to
interaction (RERI) (26).
Binomial regression was used to estimate the risk ratio (RR) of the
association between treatment exposures and these outcomes. Cox pro-
portional-hazard models were used to estimate hazard ratios (HR) for the
association between treatment exposures and mortality outcomes. Assess-
ment of the proportional-hazard assumption (PHA) was performed using
graphical methods (ln-ln survival plot) and by adding an interaction be-
tween each of the model predictors and (log) time. Corresponding 95%
confidence intervals (CIs) were estimated to measure the precision for
each estimate of exposure and outcome association.
Abstraction forms were entered into Microsoft Office Access (2007),
and data analyses were performed using SAS, version 9.2 (SAS Institute,
Cary, NC). Investigators recorded all information on a standardized ab-
straction form developed in collaboration with epidemiologists and clini-
cians.
Research ethics. This study was approved by both the Duke University
Medical Institutional Review Board (IRB) and the University of Chapel
Hill Biomedical IRB. Both named IRBs waived the need for informed
consent for this study. This research met criteria for a waiver of informed
consent according to 45 Code of Federal Regulations (CFR) 46.116(d).
RESULTS
Baseline characteristics. There were 204 patients with records
describing their antifungal treatment; 129 (63%) patients had se-
vere disease defined as requiring amphotericin B induction treat-
ment, and there were 75 (37%) patients treated with fluconazole
as recommended for nonsevere disease. Transplant recipients
were the smallest group (n  42 [21%]), and HIV-positive (n  85
[42%]) and HIV-negative, nontransplant patients (n  77 [38%])
composed the remainder of the cohort. The majority of patients
presenting at DUMC had CNS disease (n  126 [62%]), and pul-
monary disease was seen in about a third of all cases (n  69
[34%]). In addition to CNS disease patients, three patients from
the “other” disease category (n  9 [4%]) also fit the definition for
severe disease requiring amphotericin B induction treatment. The
average lengths of follow-up did not differ substantially between
groups (mean, 254 days for severe disease and 273 days for non-
severe disease).
Patients differed considerably with regard to presenting symp-
toms and conditions based on severity of cryptococcosis, although
the durations of symptoms prior to presentation were similar in
range. As expected, patients with nonsevere cryptococcosis (n 
75) had fewer neurological symptoms than patients with cases
involving the CNS. Diagnostically, among those who had a lum-
bar puncture (LP) procedure (n  176), 70% of whom had at least
one opening pressure measurement (n  99 for severe disease and
n  24 for nonsevere disease), the proportion of patients with a
maximum opening pressure of at least 20 cm H2O was high for
both severe (78%) and nonsevere (54%) cryptococcosis patients.
Notably, among those who received an LP, opening pressure mea-
surements were missing for 21% of severe disease patients and
53% of nonsevere disease patients.
Baseline covariate measures prior to starting therapy according
to patient status regarding our four main treatment exposures are
shown in Tables 1 and 2. Patients who received their recom-
mended therapy and severe disease patients who received flucyto-
sine combination therapy had higher frequencies of symptoms
and diagnostics indicating CNS disease (headache, vomiting and
nausea, altered mental status, high CRAG titers) than did patients
who did not receive the recommended initial therapy. This trend
was not seen when looking at initial treatment dose, which showed
very few variations in covariate frequencies between exposure
groups, except for altered mental status and high serum CRAG
titer (Tables 1 and 2).
Severe disease patients who received flucytosine combination
initial therapy had lower frequencies of pulmonary symptoms
(shortness of breath and cough), but a higher proportion of pa-
tients had a longer duration of symptoms (14 days) and diag-
nostic evidence of CNS disease (India ink, high cerebrospinal fluid
[CSF] CRAG titer) than did those who did not receive flucytosine
(Table 1). Patients given a shorter length of flucytosine exposure
(0 to 7 days) had a higher proportion taking corticosteroids at
the time of diagnosis, with reported weight loss, and with highly
active antiretroviral therapy (HAART) exposure (among HIV-
positive patients) than for patients given 7 days of flucytosine,
who had a higher proportion with positive blood and CNS cul-
tures, India ink, and organ transplants (Tables 1 and Table 2).
Antifungal treatment. Initial antifungal therapy type was con-
sidered appropriate given the disease severity for the majority of
patients (88% [Table 3]). Only 11 patients (9%) with severe dis-
ease (n  129) were not given amphotericin B induction therapy
within 5 days of starting therapy; 7 of these patients were eventu-
ally given induction treatment (Table 3). Fourteen patients (19%)
that fulfilled the definition of nonsevere cryptococcosis did not
receive fluconazole for initial antifungal therapy. Rather, ampho-
tericin B was used. Given the severity of disease, appropriate ther-
apy was similar in prevalence between underlying risk groups:
88% (n  75) of HIV-positive patients received appropriate ther-
apy, and 84% (n  39) of transplant recipients and 93% (n  65)
of HIV-negative/nontransplant patients received appropriate an-
tifungal therapy.
There were 192 patients (94%) with available initial treatment
dose information (Table 4). The mean dose of AmpBd was 0.66
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mg/kg/day (interquartile range [IQR], 0.56 to 0.73 mg/kg/day).
Mean doses for lipid products of amphotericin B were similar and
generally within the recommended range (Table 4), but ABLC was
used slightly more often and at slightly higher doses than L-AmpB.
The fluconazole dose averaged 350 mg/day (IQR, 208 to 400 mg/
day [Table 4]), which was close to the recommended 400 mg/
day for primary therapy and was lowest for HIV-positive patients
(data not shown).
Overall, 66% of patients received appropriate dosing of their
initial therapy and the remainder were universally underdosed
(Table 4). Dosing for severe patients was below the recommended
range for 42 (36%) patients, and this was similar for nonsevere
patients (n  24 [32%)] Furthermore, 43% of patients who re-
ceived AmpBd and 27% of patients who received fluconazole did
not receive appropriate dosing of therapy, while approximately
13% of patients who received lipid formulation amphotericin B
(LFAmpB) did not receiving appropriate dosing. Among patients
with severe disease, AmpBd formulation was within the recom-
mended range of 0.7 to 1.0 mg/kg/day for 50 patients (57%) (Ta-
ble 4) and tended to be outside the recommended range for HIV-
negative patients in particular (data not shown). Median
cumulative dose of initial therapy for patients who did not switch
therapy is shown in Table S1 in the supplemental material.
Treatment for severe disease. Flucytosine (5FC) was incorpo-
rated into initial therapy in 77% of patients with severe cryptococ-
cosis (Fig. 2). In this group, 79% of HIV-positive patients received
flucytosine with initial therapy; 83% of transplant patients and
70% of HIV-negative/nontransplant patients also received flucy-
tosine in combination with amphotericin B. The mean duration of
initial flucytosine was 11.8 days (standard deviation [SD], 6.3
days). Only 37% of the 101 patients who received any flucytosine
continued the drug for at least 14 days as recommended (Fig. 2).
Among patients who received any formulation of amphoteri-
cin B as initial therapy (n  118) and survived for at least 14 days
since the start of therapy (n  106), 56 patients (53%) completed
14 days of amphotericin B treatment. Seventy-five patients
(58%) did not switch from their initial amphotericin B formula-
tion (Table 3). Among the 14-day survivors (n  106), patients
who switched from their initial amphotericin B treatment experi-
enced significantly longer treatment exposure than those who did
not (difference in means  6 days; 95% CI, 3 to 9 days).
Treatment for nonsevere disease. Most nonsevere disease pa-
tients (81%) received fluconazole as the initial antifungal therapy
(Table 3). There were 10 (13%) patients with nonsevere disease
who later changed initial treatment, compared to 50 (39%) severe
disease patients (Table 3). This continuity of initial therapy was
significantly higher than that among patients with severe disease
(RRcrude, 1.4; 95% CI, 1.2 to 1.7). Of the patients given fluconazole
as the initial therapy, 33 patients (54%) completed 90 days of
treatment, while prior to 90 days, 2 patients were lost to follow-up
and 6 died (one death was attributable to cryptococcosis). Fifty-
two patients (72%) completed 30 days of fluconazole treatment
among those surviving at least that long (n  72).
Persistence of cryptococcosis. Persistence of infection was
common 2 weeks after the start of therapy (47% [Table 5]) among
patients with severe disease. Overall persistence at 4 weeks after
the start of therapy was 25%; the rates of persistence were 33%
among severe and 11% among nonsevere patients.
Patient mortality. Mortality in the first year after the start of
cryptococcosis treatment was high (Table 5), with an attributable
mortality rate through 1 year of 15% (n  30). The all-cause
mortality rate through 1 year of follow-up was 25% (n  52).
Notably, half of attributable deaths (n  15) were among HIV-
negative/nontransplant cases. The acute mortality rate was high
TABLE 1 Baseline covariates prior to starting antifungal therapy by exposure status (recommended therapy according to IDSA guidelines and
flucytosine exposure among patients with severe disease)
Parameter






Flucytosine exposure days, severe
2-wk survivors
Yes
(n  179) %
No
(n  25) %
Yes
(n  126) %
No
(n  66) %
Yes
(n  101) %
No
(n  28) %
7 days
(n  35) %
7 days
(n  81) %
Age  44 yrsa 97 54 9 36 69 55 30 45 46 46 16 57 14 40 41 51
Symptom length  14 daysa 70 39 12 48 53 42 27 41 48 48 7 25 11 31 40 49
Severe disease 118 66 11 44 75 60 42 64 100 100 0 35 100 NAc
No symptoms 18 10 3 12 15 12 6 9 1 1 0 1 1 0
Altered mental status 46 26 1 4 27 21 1 2 36 36 10 36 12 34 26 32
Headache 80 45 7 28 51 40 31 47 69 68 11 39 23 66 54 67
Cough 33 18 7 28 25 20 13 20 13 13 6 21 6 17 10 12
Shortness of breath 29 16 11 44 26 21 12 18 8 8 7 25 5 14 8 10
Night sweats 16 9 4 16 13 10 6 9 8 8 2 7 2 6 7 9
Fever 72 40 12 48 52 41 24 36 45 45 14 50 14 40 36 44
Nausea 57 32 5 20 38 30 19 29 39 39 11 39 15 43 33 41
Vomiting 47 26 3 12 29 23 16 24 32 32 9 32 12 34 27 33
Seizures 10 6 2 8 5 4 7 11 9 9 2 7 3 9 5 6
Weight loss 27 15 4 16 17 13 12 18 20 20 5 18 11 31 13 16
Renal insufficiency 28 16 4 16 21 17 8 12 14 14 3 11 4 11 13 16
Liver insufficiency 10 6 0 6 5 3 5 6 6 1 4 1 1 5 6
Current steroid exposure 65 36 10 40 47 37 23 35 33 33 7 25 6 17 28 35
Hematologic malignancy 10 6 5 20 11 9 4 6 5 5 3 11 4 11 1 1
Nonhematologic
malignancy
5 3 1 4 4 3 2 3 1 1 1 4 1 1 1 1
Transplant recipient 39 22 3 12 30 24 9 14 15 15 3 11 3 9 15 19
HIV positive 76 42 10 40 53 42 29 44 59 58 15 54 23 66 45 56
Exposure to HAARTb 30 39 6 60 22 42 12 41 20 34 11 73 16 70 14 31
a Median values for age and duration of symptoms were used to create binary categories.
b Among HIV-positive patients only. Percentages for this variable reflect the total number of HIV-positive patients in each column (refer to the row above for denominator).
c NA, not available.
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among patients with severe disease. Twenty-six (20%) patients
died due to cryptococcosis, and half of these deaths were during
the first 2 weeks while patients received induction treatment; three
additional patients died through 4 weeks of follow-up. Among
patients with severe disease, 10 (10%) who did not complete full
induction therapy died. Among those who did not switch from
their initial amphotericin B therapy (n  75), there were 12 deaths
attributable to cryptococcosis (16%), which was similar to the 9
deaths among the 43 patients (21%) who switched their ampho-
tericin B induction regimen. Nonsevere disease patients had lower
mortality rates; three deaths (5%) occurred within the first month
of follow-up from the start of induction therapy.
Appropriate initial treatment. The risk of persistence 2 weeks
from starting therapy among surviving severe disease patients
who did not receive recommended treatment was 1.4 (95% CI, 0.6
to 3.0) relative to those who received appropriate initial therapy
(Table 6). The risk of persistence at 4 weeks out from treatment
among all surviving patients who did not initially receive the rec-
ommended antifungal treatment was higher (RR, 1.9; 95% CI, 0.9
to 4.3 [Table 6]). If patient deaths during 2 and 4 weeks were
considered persistent infection, the corresponding RRs were 1.2
(95% CI, 0.6 to 2.7) and 1.6 (95% CI, 0.7 to 3.3).
The association between appropriate initial treatment and pa-
tient mortality was weak (Table 6). The adjusted HR for crypto-
coccosis-attributable mortality through 1 year of follow-up for
initial treatment was 0.8 (95% CI, 0.3 to 1.8). The hazard of overall
mortality through 1 year of follow-up among patients who did not
receive the recommended antifungal treatment was 1.1 times the
hazard of those who received the recommended initial treatment
(95% CI, 0.4 to 3.2), adjusted for underlying hematologic malig-
nancy and severe disease.
Appropriate initial treatment dose. Treatment dose had no
discernible association with the outcome of persistence (Table 6).
There was no significant association between the relative risk of
persistence at 4 weeks out from treatment among surviving pa-
tients who did not receive recommended antifungal treatment
dosing compared to those who initially received the recom-
mended dosing (RR, 1.1; 95% CI, 0.6 to 1.8). Among patients with
severe disease, the adjusted RR of treatment doses outside the
recommended range and 2-week persistence was also close to null
(Table 6). If patient deaths during 2 and 4 weeks were considered
persistent infection, the corresponding RRs were similar: 1.1 (95%
CI, 0.9 to 1.4) and 1.2 (95% CI, 0.8 to 1.8).
The hazard rate of cryptococcosis-attributable mortality
among patients who received treatment dosing outside what was
recommended was 2.3 times the rate among patients who received
the recommended dosing (95% CI, 1.0 to 5.0) after adjusting for
underlying hematologic malignancy, severe disease, and positive
blood culture (Table 6). The adjusted HR for overall mortality was
1.3 (95% CI, 0.7 to 2.4), adjusting for underlying hematologic
malignancy and positive blood culture.
Flucytosine use among severe cases. The RR of 2-week persis-
tence and receiving flucytosine was similar to the RR at 4 weeks
(Table 6). Among patients with severe disease (n  129) for which
TABLE 2 Patient diagnostics at baseline prior to starting antifungal therapy, stratified by to exposure status (recommended therapy according to
IDSA Guidelines and flucytosine exposure among patients with severe disease)
Patient diagnostic










(n  179) %
No
(n  25) %
Yes
(n  126) %
No
(n  66) %
Yes
(n  101) %
No
(n  28) %
7 days
(n  35) %
7 days
(n  81) %
Positive cultures
CNS—first LPa 96 54 6 24 59 47 35 53 84 83 17 61 24 69 69 85
Blood 56 31 10 40 38 30 24 36 42 42 10 36 10 29 35 43
Pulmonary 39 22 7 28 29 23 15 23 7 7 3 11 3 9 8 10
Histological evidence
of Cryptococcus
52 29 8 32 38 30 20 30 15 15 3 11 7 20 10 12
Serum antigen titer
 1:1,024
78 44 10 40 58 46 26 21 64 51 11 39 21 60 49 60
First LPb
CSF antigen titer 
1:1,024
48 33 2 13 87 82 45 82 44 44 5 23 10 30 32 40
CSF/serum glucose
ratio  0.6
117 82 14 70 78 78 45 83 90 93 20 87 27 82 74 95
CSF glucose  40 69 45 6 30 47 44 20 36 58 58 16 67 18 53 52 64
CSF protein  45 143 86 14 70 31 32 17 33 91 94 23 96 29 88 77 97
Positive India ink
stain
61 44 1 5 36 37 23 46 55 63 6 2 11 35 44 60
Peak LP OP  20 cm
H2O
b
78 72 10 67 58 73 21 58 64 79 11 61 21 78 49 75
a A total of 176 patients had an LP performed. Denominators used for percentages according to exposure (across) were 145, 15, 106, 55, 101, 23, 33 and 81 (CSF antigen titer  1:
1,024); 143, 20, 100, 54, 97, 23, 33, and 78 (CSF/serum glucose ratio  0.6); 153, 20, 107, 55, 100, 24, 34, and 81 (CSF glucose  40); 166, 20, 98, 51, 97, 24, 33, and 79 (CSF protein
 45); and 138, 19, 97, 50, 88, 23, 31, and 73 (positive India ink stain).
b In an effort to capture more opening pressure (OP) measurements, maximum LP OP was used for this variable, as the first LP did not always measure OP. There were 123
(70%) patients who had an LP OP reading among those receiving an LP (n  176). Denominators used for percentages according to exposure (across) were 108, 15, 79, 36,
81, 18, 27, and 65.
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flucytosine in combination with amphotericin B treatment is rec-
ommended, the adjusted risk of persistence at 4 weeks from initi-
ation of treatment among surviving patients who received flucy-
tosine as part of initial therapy was 0.6 times the risk of those who
did not receive any flucytosine (95% CI, 0.3 to 1.3 [Table 6]). If
patient deaths during 2 and 4 weeks were considered persistent
infection, the corresponding estimates were RRs of 0.8 (95% CI,
0.5 to 1.4) and 0.8 (95% CI, 0.4 to 1.4), respectively.
The adjusted hazard of overall mortality through 1 year of fol-
low-up among patients who received flucytosine with their initial
antifungal therapy was 0.4 times the hazard of those who did not
receive flucytosine (95% CI, 0.2 to 0.9) (Table 6). The HR of at-
tributable mortality through 1 year of follow-up for flucytosine
exposure was similar though less precise (HR, 0.5; 95% CI, 0.2 to
1.2).
There was no clear association with risk of persistence (2 or 4
weeks) between patients who received 7 days of flucytosine in
combination with their primary antifungal therapy and those who
received 7 days (Table 6). Receiving 7 days of flucytosine was
protective of cryptococcosis-attributable mortality hazard com-
pared to the risk for those who received 7 days of flucytosine,
though the association was not significant (Table 6). Notably, full
flucytosine exposure was not possible for those that succumbed to
acute mortality within 14 days of starting treatment (n  13; 50%
of all attributable deaths).
Additional outcomes. Reinduction with amphotericin B treat-
ment was performed in 25% (n  29) of severe disease patients
and 7% (n  5) of nonsevere disease patients (Table 5). IRIS was
diagnosed rarely (n  7 [3%]) among all patients surviving
through the end of initial therapy, and most of these diagnoses
were among patients with severe disease (n  6).
Pertaining to severe disease patients, renal toxicity during ini-
tial treatment occurred in approximately one-third of cases (n 
33), and 26 of these patients did not complete 14 days of induction





No. % No. % No. %
Initial therapy AmpBd 18 9 13 10 5 7
AmpBd  5FC 88 43 82 64 6 8
ABLC 5 2 2 2 3 4
ABLC  5FC 12 6 12 9 0
L-AmpB 2 1 2 2 0
L-AmpB  5FC 7 3 7 5 0
Fluconazole 71 34 10 7 61 81
Other 1 1 1 1 0
Total no. of patients 204 129 75
Total no. or % of patients on appropriate therapya 179 88 118 92 61 81
Initial doseb
AmpBd (n  98) 54 55 50 57 4 36
ABLC (n  15) 13 87 10 9 3 4
L-AmpB (n  8) 7 88 7 6 0
Fluconazole (n  71) 52 73 8 7 44 57
Total no. of patients 192 117c 75c
Total no. or % of patients on appropriate dose 126 66 75 64 51 68
Therapy changes
Fluconazole only 60 29 3 2 57 76
AmpBd only 60 29 53 41 7 9
LFAmpB only 23 11 22 17 1 1
Voriconazole only 1 1 1 1 0
Fluconazole to AmpBd 9 4 6 5 3 4
Fluconazole to LFAmpB 2 1 1 1 1 1
AmpBd to LFAmpB 46 23 42 33 4 5
LFAmpB to AmpBd 3 2 1 1 2 3
Total no. of patients 204 129 75
Total no. or % for whom therapy changed 60 29 50 39 10 13
a Therapy was appropriate (recommended) with respect to the 2010 IDSA guidelines (1).
b Initial therapy dose was within appropriate (recommended) range for each drug defined by the 2010 IDSA guidelines (1).
c Denominators for each drug by severity of disease are 87, 12, 8, and 10 patients for severe disease and 11, 3, 0, and 61 patients for nonsevere disease.
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treatment. Out of the 33 cases with renal toxicity, 19 (58%) pa-
tients switched from their initial therapy. Fifteen of these 19 pa-
tients who experienced renal toxicity and switched initial therapy
did not complete 14 days of induction treatment. Of the remain-
ing 14 patients who experienced renal toxicity but did not switch
from their initial therapy, 11 did not complete 14 days of induc-
tion treatment. Among the patients surviving at least 14 days (el-
igible to switch therapy within recommended treatment length),
evidence of renal toxicity was associated with a higher relative risk
of switching initial treatment (RRcrude, 1.9; 95% CI, 1.0 to 3.3).
DISCUSSION
This study of cryptococcal management provides important in-
sights into the disease in an advanced treatment center and pres-
ents additional data and support for the current IDSA guidelines.
Retrospective reviews have limitations. However, they can pro-
vide crucial knowledge about “real-world” effectiveness of ther-
apy that is not captured in randomized controlled studies. The
outcomes of individual cases are subject to underlying disease,
toxicity of medications, and difficulties in understanding compli-
cations, such as IRIS and increased intracranial pressure. By
studying the effectiveness of therapy, we can evaluate the current
standards of care and their real-world outcomes and identify ob-
stacles for improving that care.
There were important differences in symptoms, underlying
conditions, and diagnostics based on cryptococcosis disease sever-
ity. Of note, elevated cerebrospinal fluid opening pressure was
prevalent in two divergent groups (one with and one without in-
dicators of central nervous system disease). This result was inter-
esting knowing that the nonsevere group was negative for central
nervous system cryptococcosis, yet the high frequency of missing
values hinders interpretation. It demonstrates that an elevated ce-
rebrospinal fluid opening pressure in patients with neurological
symptoms can be an indicator for intracranial management (27),
but the potentially low specificity observed in our study suggests
that it may not serve as a precise diagnostic tool, as it is presently
measured at the bedside with a manometer. However, in clinical
practice, intracranial pressure measurements are importantly
linked to other neurological symptoms of disease such as head-
ache or altered mental status. All of these factors remain essential
for treatment and resolution of cryptococcal meningitis (28), but
better and more precise measurement technology may be war-
ranted.
Overall, appropriate initial treatment of cryptococcosis was
high over the 14-year study period, with a recommended thera-
peutic regimen being used for 88% of patients and the recom-
mended dosing being followed in 66% of patients. Despite small
numbers and the retrospective nature of this study, there was fa-
vorable evidence for compliance and clinical results supporting
the IDSA guidelines, but increased adherence may improve clini-
cal outcome. For instance, patients not receiving initial recom-
mended treatment regimens had a higher risk of persistent infec-
tion at 4 weeks (RR, 1.9) and a higher attributable mortality (RR,
2.3) in those not receiving the recommended dose. However, over
TABLE 4 Dosing of initial induction therapy and baseline disease




Dosagea for patient group
Total (n  192)b Severe (n  117)c
Nonsevere
(n  75)c
Mean IQR Mean IQR Mean IQR
Amphotericin B
(n  121)
AmpBd 0.66 0.56–0.73 0.66 0.57–0.73 0.65 0.48–0.84
ABLC 4.90 4.62–5.20 4.86 4.54–5.14 5.06 4.80–5.47
L-AmpB 4.28 3.29–5.05 4.28 3.29–5.05 NAd
Fluconazole
(n  71)
350 208–400 367 400–400 346 208–400
a Fluconazole dosing is in mg/day. All other medications are in mg/kg/day.
b Twelve patients were missing information on initial treatment dose (either dosing or
body weight information).
c Denominators for each antifungal drug (top to bottom) are 87, 12, 8, and 10 patients
for severe disease and 11, 3, 0, and 61 patients for nonsevere disease.
d NA, not available.
FIG 2 Duration of flucytosine combination treatment with initial primary therapy (severe disease; n  129).
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one-third of patients did change from their initial therapy; 28% of
these patients were switched from a nonrecommended to a rec-
ommended therapy given their disease severity. The consequences
of this change in therapy resulted in patients who experienced an
overall longer duration of induction than did those who did not
change therapy.
Flucytosine was used in 78% of severe disease patients for ini-
tial therapy, but only 37% of these recipients continued combina-
tion treatment for at least 14 days. High acute mortality (prior to
completion of induction) and renal toxicity among severe disease
patients likely contributed to this high incompletion rate. None-
theless, patients receiving flucytosine combination therapy expe-
rienced lower rates of overall and attributable mortality than those
patients who did not receive any flucytosine. However, receiving
more than 7 days of flucytosine was not significantly associated
with lower mortality rates than for those who received at most 7
days, suggesting that early acute mortality may not be preventable
with flucytosine use but is a consequence of other underlying fac-
tors, such as malignancy or AIDS, contributing to poor patient
outcome. On the other hand, the observed protective effects of
flucytosine support a growing body of evidence that combination
therapy is important to a positive outcome (8, 10, 29). The poly-
ene and flucytosine combination has consistently demonstrated
its superior success, with retrospective data identifying better out-
comes at 2 weeks (8), prospective randomized trial data on fungi-
cidal activity in the CSF (29), and correlation with this fungicidal
activity and outcome (30, 31). Thus, our study highlights the im-
portance of increased use of flucytosine. This may be improved
with rapid-access flucytosine levels and/or close follow-up of
complete blood counts— elements needed to increase the likeli-
hood patients will receive at least 2 weeks of flucytosine.
By our definition persistence at 2 weeks was a common out-
come, but 75% of patients through 4 weeks did have documented
resolution of symptoms and microbiological signs of disease. The
percentage of patients with disease resolution through 4 weeks
falls into the same range of outcomes as previously published co-
horts (6, 30, 32, 33). This rate of persistence of infection likely
reflects the high burden of Cryptococcus in the CSF of these pa-
tients and challenges us to be more aggressive about measuring
how our treatment regimens impact the killing of yeasts during
induction therapy.
The rate of all-cause mortality of nonsevere disease patients
TABLE 5 Patient outcomes after antifungal therapy, according to treatment exposure status
Outcome










Yes % No % Yes % No % Yes % No % 7 days % 7 days %
Persistence, 2 wksa
Yes 52 50 4 40 33 42 17 47 46 50 10 43 16 46 40 50
No 53 50 6 60 37 47 19 53 46 50 13 57 19 54 40 50
Persistence, 4 wks
Yes 39 24 6 27 26 25 15 26 29 33 8 33 11 34 26 33
No 121 76 16 73 89 85 43 74 60 67 14 67 21 66 53 67
Cryptococcosis-attributable mortality
Yes 26 15 4 16 12 10 14 21 18 11 8 29 6 17 7 9
No 153 85 21 84 114 90 52 79 83 89 20 71 29 83 74 91
1-yr mortality
Yes 41 23 8 32 26 21 18 27 22 22 12 43 7 20 14 17
No 138 77 17 68 100 79 48 73 79 78 16 57 28 80 67 83
Patient reinducedb
Yes 29 18 5 23 20 17 11 19 22 19 7 30 8 23 21 26
No 132 82 17 77 95 83 48 81 71 81 16 70 27 77 60 74
IRISc
Yes 6 4 1 5 4 3 3 5 6 6 0 0 1 3 5 6
No 155 96 21 95 111 97 57 95 87 94 23 100 34 97 76 94
Renal toxicityd
Yes 30 31 3 43 23 35 9 28 27 32 6 30 10 32 23 32
No 67 69 4 57 42 65 23 72 57 68 14 70 21 68 50 68
a Among severe cases only: 2-week persistence, n  115 (13 deaths; 1 patient with missing information); for 4-week persistence, n  182 (5 additional deaths since 2 weeks and 3
patients with missing information).
b Patient had to survive through 2 weeks for severe disease and 90 days for nonsevere disease (end of recommended treatment duration) to be eligible for denominator of
reinduction status.
c Patient had to survive through 2 weeks for severe disease and 90 days for nonsevere disease (end of recommended treatment duration) to be eligible for IRIS diagnosis.
d Drop in glomerular filtration rate of 50% (among severe disease only)—measured from the date closest to the start of therapy (week 0) to the date closest to 2 weeks after
starting therapy (week 2). Patient had to survive through 2 weeks (end of recommended treatment duration) to be eligible for renal toxicity outcome.
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(20%) was similar to that in the severe disease group (26%). When
comparing cryptococcosis-attributable mortality, the mortality
rate in the nonsevere disease patient group was found to be much
lower than the mortality rate in the severe disease patient group
(5% and 20%, respectively). Future investigation should consider
highlighting the distinction of these two mortality outcomes so as
to not overestimate the true effect of cryptococcosis on patient
death. This also serves to show that nonsevere disease also does
identify a patient with a serious underlying disease in many cases.
This difference between attributable and overall mortality rates
emphasizes how the specific underlying disease was a risk factor
for poor outcomes. For example, a hematologic malignancy was a
strong independent predictor of patient mortality in our cohort
and likely reflects the end stage of the underlying disease when
cryptococcosis appears (34, 35). Fourteen out of 15 patients with
hematologic malignancy were HIV negative and had not received
a solid-organ transplant. In fact, 50% of cryptococcosis-attribut-
able deaths were in HIV-negative, nontransplant patients with a
variety of underlying diseases. Thus, identifying background rates
of cryptococcosis and baseline risk factors for earlier diagnosis and
assessing present treatment strategies in relationship to how they
are efficiently handling the fungal burden could be very useful in
reducing morbidity and mortality rates for this group.
Four major randomized treatment trials served as important
comparators to this study and informed the treatment recom-
mendations in the current IDSA guidelines (6, 9, 10, 22). The key
difference between these studies and this cohort was that this
study was observational (nonrandomized) and used a single cen-
ter instead of multiple sites for patient recruitment. Only one
study (10) used a larger patient group for analysis, and all but one
study (22) recruited only cryptococcal meningitis patients.
Our study spanned a much longer period (14 years, compared to
5 years for the randomized trials). The continuity of care at a
single center allowed for such an extended period of in-depth
retrospective observation. However, there were striking similari-
ties between results in our study and those of these randomized
trials. First, we observed a prevalence of cure or improvement
through 4 weeks of 75%, and Dismukes et al. observed 80%
cure through 4 weeks (22). Second, van der Horst et al. reported
that through 2 weeks of combination induction therapy, 60% pa-
tients were culture negative (10). In our study, 42% of patients
with severe disease had signs of persistent infection through 2
weeks. Third, attributable mortality and overall mortality rates
were consistent with those found in three other randomized trials
(6, 9, 33). Among patients with severe disease in our study, 10%
died in the first 2 weeks. This sobering figure demonstrates that
acute mortality continues to be a serious problem despite over 3
decades of clinical study and experience. Fourth, since timing of
relapse was difficult to categorize in this observational study, re-
induction might be considered a proxy for relapse—19% of our
patients were reinduced. This finding was similar to the preva-
lence of relapse (16% in a 6-week arm and 27% in a 4-week arm)
reported by Dismukes et al. (22). This relapse rate may be artifi-
cially high secondary to lack of IRIS appreciation, although in
retrospect in our review, we found a relatively low incidence of this
condition in our cohort.
Although an observational study design was used, we obtained
results similar to those in previous randomized trials. Taking into
consideration our single-center attribute, the observed consis-
tency in treatment may have had the unintended consequence of
revealing underlying factors contributing to patient failure rather
than determining whether variations in initial treatment were
contributing to persistence of cryptococcosis or its attributable
mortality rate. In fact, positive CSF cultures, high CSF antigen-
emia, absence of headache, and long duration of symptoms prior
to admission continue to emerge in our analyses as strong predic-
tors of patient failure rather than treatment regimens. Within
these risk factors are likely buried important features of outcome
regarding high burden of yeasts and poor host inflammatory re-
TABLE 6 Final adjusted models of the influences of treatment type, dosing, and flucytosine use (severe disease only) on the risk of persistence of







Ratio 95% CI Ratio 95% CI Ratio 95% CI Ratio 95% CI
RR Persistence at 2 wks (severe only)e 1.4 0.6–3.0 1.1 0.8–1.4 0.8 0.5–1.4 0.9 0.7–1.2
Persistence at 4 wkse 1.9 0.9–4.3 1.1 0.6–1.8 0.6 0.3–1.3 0.8 0.4–1.3
HR Cryptococcosis-attributable mortality 1.1 0.4–3.2 2.3 1.0–5.0 0.5 0.2–1.2 0.6 0.2–1.8
1-yr all-cause mortality 0.8 0.3–1.8 1.3 0.7–2.4 0.4 0.2–0.9 1.1 0.4–2.7
a Patient not given recommended antifungal therapy regimen initially (1) or received recommended therapy (0). Persistence at 2 weeks was adjusted for high cryptococcal CSF
antigen titer (1:1,024). Persistence at 4 weeks was adjusted for high cryptococcal CSF antigen titer (1:1,024) and severe disease. Cryptococcosis-attributable mortality was
adjusted for underlying hematologic malignancy and positive blood culture. One-year all-cause mortality was adjusted for confounding by severe disease and underlying
hematologic malignancy.
b Patient dose for initial antifungal therapy was outside the range recommended (1) or dosing was within the recommended range (0). Persistence at 2 weeks was adjusted for high
cryptococcal CSF antigen titer (1:1,024). Persistence at 4 weeks was adjusted for severe disease. Cryptococcosis-attributable mortality was adjusted for underlying hematologic
malignancy, positive blood culture, and severe disease. One-year all-cause mortality was adjusted for confounding by positive blood culture and underlying hematologic
malignancy.
c Flucytosine was used with initial therapy among severe disease patients only (n  129). Persistence at 2 weeks was adjusted for high cryptococcal CSF antigen titer (1:1,024).
Persistence at 4 weeks was adjusted for high cryptococcal CSF antigen titer (1:1,024) and 14 days of symptoms prior to presentation; both cryptococcosis-attributable mortality
and overall mortality rates were adjusted for underlying hematologic malignancy and receipt of amphotericin B deoxycholate.
d Flucytosine exposure categories were 7 days (referent) and 7 days of exposure. Two-week persistence was adjusted for high CSF cryptococcal antigen titer (1:1,024) at first
LP; 4-week persistence was adjusted for 14 days of symptoms prior to presentation and high initial CSF cryptococcal antigen titer (1:1,024) at first LP; attributable mortality and
overall mortality rates were adjusted for underlying hematologic malignancy.
e Persistence outcomes were contingent on survival through 2 weeks and 4 weeks since the date of starting antifungal therapy.
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sponses within the CNS which must be carefully defined and mon-
itored in relationship to therapy (32).
Strengths and limitations. Our results may not be applicable
to all centers in the United States, as approaches for ancillary care
may differ. Furthermore, using hospital records favors cases with
severe disease and results in selection bias against asymptomatic
or mild disease. The total population at risk was not estimable in
this study, and the underlying source population and referral pat-
terns could shift over time.
In order to obtain a reportable picture of various outcomes, we
created definitions of severe versus nonsevere, persistence of in-
fection (2 and 4 weeks), and attributable mortality, and we used
the IDSA guidelines to define appropriate therapy. Regardless, the
overall mortality rate in patients with severe cryptococcosis re-
mains high, at almost 25% within 1 year.
This study was limited to a single tertiary care center and teach-
ing hospital. Although this could be considered a limitation, eval-
uating patients at a single center allowed us to examine a broader
time period with higher uniformity of data availability, continuity
of care, and treatment consistency. Because cryptococcosis is a
rare disease with a high acute mortality rate, smaller case numbers
limited the ability to adjust for all confounders identified in min-
imum adjustment sets and prevented robust statistical analyses of
treatment effects, but to our knowledge this study is the largest
single-center cryptococcosis cohort study, and it provides in-
depth information on a heterogeneous group of patients. It rep-
resents an important insight into how this infection is being man-
aged and what the outcomes have been. Future studies combining
our cohort with additional patient groups from other institutions
would provide beneficial robustness for treatment effectiveness
analyses.
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